Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system
British Journal of Anaesthesia · 2025
DOI: 10.1016/j.bja.2024.10.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Anaesthesia, 2025. Verfasst von Haoquan Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China; Department of Anaesthe…. Hauptthemen laut MEDLINE: Pharmacovigilance, Glucagon-Like Peptide-1 Receptor Agonists, Adverse Drug Reaction Reporting Systems, Gastric Emptying. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, Sun Yat-Sen University.
Abstract (Originalsprache)
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We analysed FAERS data from 2004 Q1 to 2024 Q1, identifying the top 10 drugs linked to IGE and determining the proportion of GLP-1RA use. Disproportionality analysis using the reporting odds ratio was conducted to assess the relative IGE risk for each drug. Logistic regression analysed the impact of age, weight, and sex on IGE risk. Cumulative incidence and time to onset of IGE events were examined using Kaplan-Meier and Weibull shape parameter tests. RESULTS: Among the top 10 drugs associated with IGE reports, five were GLP-1RAs, accounting for 49.5% (982/1982) of cases. Dulaglutide (odds ratio [OR] 0.97, 95% confidence interval [CI] 0.94-1.00, P=0.033) and semaglutide (OR 0.96, 95% CI 0.94-0.97, P=0.001) showed lower IGE risk with older age. For exenatide, higher weight (OR 0.99, 95% CI 0.98-1.00, P=0.033) and male sex (OR 0.39, 95% CI 0.20-0.68, P=0.033) were associated with lower IGE risk. Median onset times ranged from 40.5 days (semaglutide) to 107.5 days (tirzepatide) from intitiation of therapy. The Weibull shape parameter β was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesiology, Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China; Department of Anaesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangz…
- Medical Research Center of Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, China.
Förderung
- Natural Science Foundation of Guangdong Province
- Sun Yat-Sen University
Zitieren
APA
Huang, H., Hu, C., Liu, F., Ji, F., Fu, Y., & Cao, M. (2025). Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2024.10.013
Vancouver
Huang H, Hu C, Liu F, Ji F, Fu Y, Cao M. Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system. British Journal of Anaesthesia. 2025. doi:10.1016/j.bja.2024.10.013
BibTeX
@article{Huang2025,
author = {Huang, Haoquan and Hu, Chuwen and Liu, Fan and Ji, Fengtao and Fu, Yanni and Cao, Minghui},
title = {Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system},
journal = {British Journal of Anaesthesia},
year = {2025},
doi = {10.1016/j.bja.2024.10.013}
}
EUVIMED